This trial is testing a new way to treat breast cancer that has spread to the brain. Patients will receive a drug called pembrolizumab, which will be given before they undergo a type of radiation treatment called stereotactic radiosurgery.
3 Primary · 1 Secondary · Reporting Duration: 3 years
41 Total Participants · 0 Treatment Group
Primary Treatment: Treatment · No Placebo Group · Phase 1 & 2
Age 19 - 90 · Female Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: